{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T19:24:05Z","timestamp":1773689045259,"version":"3.50.1"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,8,6]],"date-time":"2022-08-06T00:00:00Z","timestamp":1659744000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,8,6]],"date-time":"2022-08-06T00:00:00Z","timestamp":1659744000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Med Res Methodol"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>The Randomised Evaluation of COVID-19 Therapy (RECOVERY) trial is aimed at addressing the urgent need to find effective treatments for patients hospitalised with suspected or confirmed COVID-19. The trial has had many successes, including discovering that dexamethasone is effective at reducing COVID-19 mortality, the first treatment to reach this milestone in a randomised controlled trial. Despite this, it continues to use standard or \u2018fixed\u2019 randomisation to allocate patients to treatments. We assessed the impact of implementing response adaptive randomisation within RECOVERY using an array of performance measures, to learn if it could be beneficial going forward. This design feature has recently been implemented within the REMAP-CAP platform trial.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Trial data was simulated to closely match the data for patients allocated to standard care, dexamethasone, hydroxychloroquine, or lopinavir-ritonavir in the RECOVERY trial from March-June 2020, representing four out of five arms tested throughout this period. Trials were simulated in both a two-arm trial setting using standard care and dexamethasone, and a four-arm trial setting utilising all above treatments. Two forms of fixed randomisation and two forms of response-adaptive randomisation were tested. In the two-arm setting, response-adaptive randomisation was implemented across both trial arms, whereas in the four-arm setting it was implemented in the three non-standard care arms only. In the two-arm trial, randomisation strategies were performed at the whole trial level as well as within three pre-specified patient subgroups defined by patients\u2019 respiratory support level.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>All response-adaptive randomisation strategies led to more patients being given dexamethasone and a lower mortality rate in the trial. Subgroup specific response-adaptive randomisation reduced mortality rates even further. In the two-arm trial, response-adaptive randomisation reduced statistical power compared to FR, with subgroup level adaptive randomisation exhibiting the largest power reduction. In the four-arm trial, response-adaptive randomisation increased statistical power in the dexamethasone arm but reduced statistical power in the lopinavir arm. Response-adaptive randomisation did not induce any meaningful bias in treatment effect estimates nor did it cause any inflation in the type 1 error rate.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Using response-adaptive randomisation within RECOVERY could have increased the number of patients receiving the optimal COVID-19 treatment during the trial, while reducing the number of patients needed to attain the same study power as the original study. This would likely have reduced patient deaths during the trial and lead to dexamethasone being declared effective sooner. Deciding how to balance the needs of patients within a trial and future patients who have yet to fall ill is an important ethical question for the trials community to address. Response-adaptive randomisation deserves to be considered as a design feature in future trials of COVID-19 and other diseases.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12874-022-01691-w","type":"journal-article","created":{"date-parts":[[2022,8,6]],"date-time":"2022-08-06T10:02:32Z","timestamp":1659780152000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Should RECOVERY have used response adaptive randomisation? Evidence from a simulation study"],"prefix":"10.1186","volume":"22","author":[{"given":"Tamir","family":"Sirkis","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Benjamin","family":"Jones","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jack","family":"Bowden","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,8,6]]},"reference":[{"key":"1691_CR1","unstructured":"CDC. Healthcare Workers [Internet]. Centers for Disease Control and Prevention. 2020 [cited 2021 Jun 24]. Available from: https:\/\/www.cdc.gov\/coronavirus\/2019-ncov\/hcp\/non-us-settings\/overview\/index.html"},{"key":"1691_CR2","unstructured":"WHO Director-General\u2019s opening remarks at the media briefing on COVID-19 - 11 March 2020 [Internet]. [cited 2021 May 31]. Available from: https:\/\/www.who.int\/director-general\/speeches\/detail\/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19%2D%2D-11-march-2020"},{"key":"1691_CR3","unstructured":"Coronavirus Pandemic (COVID-19) \u2013 the data - Statistics and Research [Internet]. Our World in Data. [cited 2021 Jun 1]. Available from: https:\/\/ourworldindata.org\/coronavirus-data"},{"issue":"370","key":"1691_CR4","doi-asserted-by":"publisher","first-page":"m3489","DOI":"10.1136\/bmj.m3489","volume":"7","author":"N Nabavi","year":"2020","unstructured":"Nabavi N. Long covid: how to define it and how to manage it. BMJ. 2020 Sep;7(370):m3489.","journal-title":"BMJ."},{"key":"1691_CR5","doi-asserted-by":"crossref","unstructured":"Whitaker M, Elliott J, Chadeau-Hyam M, Riley S, Darzi A, Cooke G, et al. Persistent symptoms following SARS-CoV-2 infection in a random community sample of 508,707 people. 2021. Available from: http:\/\/spiral.imperial.ac.uk\/handle\/10044\/1\/89844. Jun [cited 2021 Jun 27]","DOI":"10.1101\/2021.06.28.21259452"},{"issue":"4","key":"1691_CR6","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1016\/S1470-2045(21)00148-0","volume":"22","author":"TL Oncology","year":"2021","unstructured":"Oncology TL. COVID-19 and cancer: 1 year on. Lancet Oncol. 2021;22(4):411.","journal-title":"Lancet Oncol"},{"issue":"4","key":"1691_CR7","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1177\/0020764020915212","volume":"66","author":"J Torales","year":"2020","unstructured":"Torales J, O\u2019Higgins M, Castaldelli-Maia JM, Ventriglio A. The outbreak of COVID-19 coronavirus and its impact on global mental health. Int J Soc Psychiatry. 2020;66(4):317\u201320.","journal-title":"Int J Soc Psychiatry"},{"key":"1691_CR8","unstructured":"2020 Year in Review: The impact of COVID-19 in 12 charts [Internet]. [cited 2021 Jun 27]. Available from: https:\/\/blogs.worldbank.org\/voices\/2020-year-review-impact-covid-19-12-charts"},{"key":"1691_CR9","unstructured":"University of Oxford. Randomised Evaluation of COVID-19 Therapy [Internet]. clinicaltrials.gov; 2021 Apr [cited 2021 May 27]. Report No.: NCT04381936. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04381936"},{"key":"1691_CR10","doi-asserted-by":"crossref","unstructured":"Effect of hydroxychloroquine in hospitalized patients with Covid-19. N Engl J Med. 2020;383(21):2030\u201340.","DOI":"10.1056\/NEJMoa2022926"},{"key":"1691_CR11","unstructured":"Lopinavir\u2013ritonavir in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial - The Lancet [Internet]. [cited 2022 Mar 22]. Available from: https:\/\/www.thelancet.com\/journals\/lancet\/article\/PIIS0140-6736(20)32013-4\/fulltext"},{"key":"1691_CR12","doi-asserted-by":"crossref","unstructured":"Dexamethasone in hospitalized patients with Covid-19. N Engl J Med. 2021;384(8):693\u2013704.","DOI":"10.1056\/NEJMoa2021436"},{"issue":"10285","key":"1691_CR13","doi-asserted-by":"publisher","first-page":"1637","DOI":"10.1016\/S0140-6736(21)00676-0","volume":"397","author":"O Abani","year":"2021","unstructured":"Abani O, Abbas A, Abbas F, Abbas M, Abbasi S, Abbass H, et al. Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet. 2021;397(10285):1637\u201345.","journal-title":"Lancet"},{"key":"1691_CR14","unstructured":"Group RC, Horby PW, Mafham M, Peto L, Campbell M, Pessoa-Amorim G, et al. Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. medRxiv. 2021; Jun 16;2021.06.15.21258542."},{"key":"1691_CR15","unstructured":"Recommendations | COVID-19 rapid guideline: managing COVID-19 | Guidance | NICE [Internet]. NICE; [cited 2021 Jul 15]. Available from: https:\/\/www.nice.org.uk\/guidance\/ng191\/chapter\/Recommendations"},{"issue":"10","key":"1691_CR16","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1038\/s41573-019-0034-3","volume":"18","author":"DC Angus","year":"2019","unstructured":"Angus DC, Alexander BM, Berry S, Buxton M, Lewis R, Paoloni M, et al. Adaptive platform trials: definition, design, conduct and reporting considerations. Nat Rev Drug Discov. 2019;18(10):797\u2013807.","journal-title":"Nat Rev Drug Discov"},{"issue":"1","key":"1691_CR17","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1186\/s12916-018-1017-7","volume":"16","author":"P Pallmann","year":"2018","unstructured":"Pallmann P, Bedding AW, Choodari-Oskooei B, Dimairo M, Flight L, Hampson LV, et al. Adaptive designs in clinical trials: why use them, and how to run and report them. BMC Med. 2018;16(1):29.","journal-title":"BMC Med"},{"issue":"11","key":"1691_CR18","doi-asserted-by":"publisher","first-page":"3002","DOI":"10.1093\/cid\/ciaa334","volume":"71","author":"M Proschan","year":"2020","unstructured":"Proschan M, Evans S. Resist the temptation of response-adaptive randomization. Clin Infect Dis. 2020;71(11):3002\u20134.","journal-title":"Clin Infect Dis"},{"key":"1691_CR19","doi-asserted-by":"crossref","unstructured":"Interleukin-6 receptor antagonists in critically ill patients with Covid-19. N Engl J Med. 2021;384(16):1491\u2013502.","DOI":"10.1056\/NEJMoa2100433"},{"key":"1691_CR20","unstructured":"Bonten MJM. Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia. clinicaltrials.gov. 2020; Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02735707. [cited 2021 May 26]. Report No.: NCT02735707."},{"key":"1691_CR21","unstructured":"Core R. Team. R: a language and environment for statistical computing [internet]. Vienna, Austria: R Foundation for Statistical. Computing. 2020; Available from: https:\/\/www.R-project.org\/."},{"issue":"3","key":"1691_CR22","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1111\/j.0006-341X.2001.00909.x","volume":"57","author":"WF Rosenberger","year":"2001","unstructured":"Rosenberger WF, Stallard N, Ivanova A, Harper CN, Ricks ML. Optimal adaptive designs for binary response trials. Biometrics. 2001;57(3):909\u201313.","journal-title":"Biometrics."},{"issue":"5","key":"1691_CR23","doi-asserted-by":"publisher","first-page":"2376","DOI":"10.1177\/0962280215597716","volume":"26","author":"J Bowden","year":"2017","unstructured":"Bowden J, Trippa L. Unbiased estimation for response adaptive clinical trials. Stat Methods Med Res. 2017;26(5):2376\u201388.","journal-title":"Stat Methods Med Res"},{"key":"1691_CR24","unstructured":"Robinson J. Steroid has saved the lives of one million COVID-19 patients worldwide, figures show. Pharm J. 2021; Available from: https:\/\/pharmaceutical-journal.com\/article\/news\/steroid-has-saved-the-lives-of-one-million-covid-19-patients-worldwide-figures-show."},{"issue":"7","key":"1691_CR25","doi-asserted-by":"publisher","first-page":"2131","DOI":"10.1161\/STROKEAHA.114.005418","volume":"45","author":"JS Tehranisa","year":"2014","unstructured":"Tehranisa JS, Meurer WJ. Can response-adaptive randomization increase participation in acute stroke trials? Stroke. 2014;45(7):2131\u20133.","journal-title":"Stroke."},{"issue":"20","key":"1691_CR26","doi-asserted-by":"publisher","first-page":"2191","DOI":"10.1001\/jama.2013.281053","volume":"310","author":"World Medical Association Declaration of Helsinki","year":"2013","unstructured":"World Medical Association Declaration of Helsinki. Ethical principles for medical research involving human subjects. JAMA. 2013;310(20):2191.","journal-title":"JAMA."},{"issue":"2","key":"1691_CR27","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1002\/pst.1845","volume":"17","author":"SS Villar","year":"2018","unstructured":"Villar SS, Bowden J, Wason J. Response-adaptive designs for binary responses: how to offer patient benefit while being robust to time trends? Pharm Stat. 2018;17(2):182\u201397.","journal-title":"Pharm Stat"},{"issue":"12","key":"1691_CR28","doi-asserted-by":"publisher","first-page":"e95","DOI":"10.1016\/S2213-2600(20)30461-6","volume":"8","author":"P Venkatesan","year":"2020","unstructured":"Venkatesan P. The changing demographics of COVID-19. Lancet Respir Med. 2020;8(12):e95.","journal-title":"Lancet Respir Med"},{"issue":"6","key":"1691_CR29","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1001\/jama.2020.27124","volume":"325","author":"AS Lauring","year":"2021","unstructured":"Lauring AS, Hodcroft EB. Genetic variants of SARS-CoV-2\u2014what do they mean? JAMA. 2021;325(6):529.","journal-title":"JAMA."},{"issue":"370","key":"1691_CR30","doi-asserted-by":"publisher","first-page":"m2670","DOI":"10.1136\/bmj.m2670","volume":"8","author":"J Wise","year":"2020","unstructured":"Wise J, Coombes R. Covid-19: the inside story of the RECOVERY trial. BMJ. 2020;8(370):m2670.","journal-title":"BMJ."},{"issue":"4","key":"1691_CR31","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1177\/216847900604000409","volume":"40","author":"JA Quinlan","year":"2006","unstructured":"Quinlan JA, Krams M. Implementing adaptive designs: logistical and operational considerations. Drug Inf J. 2006;40(4):437\u201344.","journal-title":"Drug Inf J"},{"issue":"371","key":"1691_CR32","doi-asserted-by":"publisher","first-page":"m4296","DOI":"10.1136\/bmj.m4296","volume":"5","author":"G Iacobucci","year":"2020","unstructured":"Iacobucci G. Covid-19: NHS is placed on highest alert level as intensive care beds fill up. BMJ. 2020;5(371):m4296.","journal-title":"BMJ."},{"key":"1691_CR33","unstructured":"UK. Daily new hospital admissions for COVID-19. Our World in Data. 2021; Available from: https:\/\/ourworldindata.org\/grapher\/uk-daily-covid-admissions."}],"container-title":["BMC Medical Research Methodology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12874-022-01691-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12874-022-01691-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12874-022-01691-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,6]],"date-time":"2022-08-06T10:03:31Z","timestamp":1659780211000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcmedresmethodol.biomedcentral.com\/articles\/10.1186\/s12874-022-01691-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,6]]},"references-count":33,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["1691"],"URL":"https:\/\/doi.org\/10.1186\/s12874-022-01691-w","relation":{},"ISSN":["1471-2288"],"issn-type":[{"value":"1471-2288","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,6]]},"assertion":[{"value":"4 January 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 July 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 August 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"216"}}